Multi-center, Canadian, Non-interventional, Cohort Study of the Effectiveness, Safety, Adherence, and Health-related Quality of Life in HIV-1 Infected Adult Patients Receiving Bictegravir/ Emtricitabine/Tenofovir Alafenamide (B/F/TAF)
Latest Information Update: 17 Nov 2024
At a glance
- Drugs Bictegravir/emtricitabine/tenofovir alafenamide (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms BIC-STaR; BICSTaR
- Sponsors Gilead Sciences
- 07 Nov 2024 According to a Gilead Sciences media release, four-year outcomes data from this study will be presented at the International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2024), taking place from November 10-13.
- 25 Jul 2024 According to a Gilead Sciences media release, data from the study were presented at the 25th International AIDS Conference (AIDS 2024).
- 25 Jul 2024 Results presented in the Gilead Sciences Media Release